Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) is a Healthcare company (Biotechnology) with a market capitalization of $447M. The Maz Rating grades it against the other companies in its sector.
Phathom Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.50, Phathom Pharmaceuticals, Inc. trades at 1.6x sales. Over the last twelve months it generated about $275M of revenue and a net loss of $84M. It runs a gross margin of 80.7%, an operating margin of -9.3% and a net margin of -30.2%. It shows return on equity of 29.7%, return on invested capital of -14.9% and a free cash flow yield of -4.7%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 1.76. Over the past 52 weeks the share price ranged from $5.01 to $18.31, with a beta of 0.50.
Phathom Pharmaceuticals, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 8 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.